Beqvez: a one-time gene therapy for hemophilia B (with a commercial caveat)

Published · Researched 2026-09-22

What happened (dated facts)

On April 26, 2024, the U.S. FDA approved Beqvez (fidanacogene elaparvovec), a one-time gene therapy for adults with hemophilia B. In the pivotal BENEGENE-2 study, the mean annualized bleeding rate fell to 2.5 after treatment versus 4.5 during the prophylaxis lead-in; bleeds were eliminated entirely in 60% of patients versus 29% on standard factor prophylaxis, and the median annualized bleeding rate was zero. In February 2025, Pfizer announced it was ending global development and commercialization of Beqvez, citing low demand, high cost, durability concerns, and competing treatment advances — the therapy's medical achievement stands, but its commercial future does not. This dossier is retained on the strength of the clinical outcome; the discontinuation is disclosed, not hidden.

Why it is genuinely positive

Hemophilia B means lifelong factor infusions. A single infusion that drove the median bleeding rate to zero and eliminated bleeds in three of five patients is a genuine clinical advance — the outcome data is what makes it positive, regardless of the manufacturer's business decision.

Social pulse

On Threads (searched 2026-09-22), the Beqvez approval was circulating via medical and news accounts: @medicalletter posted "Beqvez — Another Gene Therapy for Hemophilia B... Fidanacogene elaparvovec-dzkt (Beqvez – Pfizer), an adeno-associated virus (AAV) vector-based gene therapy, is the second single-dose gene therapy to be approved in the US for treatment of hemophilia B," and @anhadjakhmola shared "Pharmaceutical giant Pfizer won US approval for its first gene therapy... The treatment, called Beqvez, gained clearance for patients with hemophilia B." The approval story is genuinely circulating on social. (The February 2025 commercial discontinuation is disclosed in the dossier as a business decision, not a medical reversal.)

Verified quotes

None captured.

Verification

• Tier: 2
• Primary source: Drugs.com drug history for Beqvez (https://www.drugs.com/history/beqvez.html). Proves: approval April 26, 2024; mean ABR 2.5 vs 4.5; 60% vs 29% bleed-free; median ABR zero. Commercialization ended February 2025 (Pfizer announcement via coverage).
• Social sources: Threads — @medicalletter (Beqvez gene-therapy explainer post); @anhadjakhmola (Pfizer approval news post). Proves: the approval story is circulating on social via medical and news accounts.
• Positivity check: large measured bleeding reduction — genuine; commercial discontinuation disclosed as a caveat. If the strict positivity standard bars this slot, the ARC-EX spinal-cord stimulation reserve (FDA-authorized December 2024) is the designated replacement.

Key facts

UNVERIFIED points

• Social-layer posts about Beqvez were not yet observed; tier cannot be finalized until they are.
• Whether this slot should be substituted with ARC-EX remains an open editorial decision pending the strict positivity review.

Sources

• Primary source: Drugs.com drug history for Beqvez ( — retrieval date not recorded